Sized before you spend
Qualifying patient counts and a yearly estimate to weigh against a device, training or space.
HomeClinical Speed ForwardService Line Growth Review
Clinical Speed Forward · Program 4
We show the services you are eligible to offer but do not yet, each sized by how many of your patients already qualify. It is a planning report for leadership, never a patient list.
A planning report for leadership, never a patient list: patients are counted, never named. Estimates are upper bounds, rounded to the nearest $1,000: qualifying patients times the expected contract payment.
| Service line | Eligible through | Qualifying patients | Upper yearly estimate | To start |
|---|---|---|---|---|
| Vascular testing93922 · 93925 | Cardiology, vascular surgery | 1,140 | $612K | |
| Pulmonary rehabilitation94625 · 94626 | Pulmonology | 860 | $498K | |
| In-lab sleep testing95810 · 95811 | Pulmonology, neurology | 640 | $371K | |
| Lung cancer screening71271 | Radiology, primary care | 1,480 | $298K | |
| Diabetes self-managementG0108 · G0109 | Endocrinology, nursing | 2,310 | $164K |
Service Line Growth Review · the question it answers
Qualifying patient counts and a yearly estimate to weigh against a device, training or space.
Your provider types, the payer rules and your own diagnoses.
As new services get their codes, we show which fit your hospital.
Deliverables
Each service line you are eligible to offer but do not, with its codes and the reason you qualify: your provider types and the payer coverage rules. Ranked so leadership sees the strongest cases first.
Qualifying patients times the expected contract payment, labelled as an upper estimate, because not every qualifying patient will need or choose the service, and registry provider types can be out of date.
How many of your patients already carry the diagnoses each coverage rule requires. Counted, never named, with small counts shown as fewer than 11.
The device, the training for physicians you already have, the staff and the space, so the estimate is weighed against the real cost to start.
As new services receive their CPT, HCPCS and ICD codes, we show which ones fit your hospital, so the report keeps pace with medicine.
Inside the program
Service Line Growth Review answers a leadership question: is this service worth building here? It never names a patient, never produces a list and never suggests steering anyone toward a test. Every line it shows must be supported by coverage rules and your own patients' diagnoses, not by revenue alone.
Because no patient is named, no records access is needed. The review runs on the claims, contracts and provider roster your hospital already has, and read-only records, if you grant them, only tighten the counts.
I70.2xAtherosclerosis of native arteries of the legs520E11.51Type 2 diabetes with peripheral angiopathy410I73.9Peripheral vascular disease, unspecified210Method
Consilience reasons over the codes. It does not decide, and it does not diagnose. Your people confirm every change.
In the claim's life
Service Line Growth Review looks forward, at the services your hospital could offer next.
Eligible service lines and patient counts from claims diagnoses, provider types and coverage rules, shown as upper estimates.
Tighter patient counts, because qualifying results and severity come from the record. Still counts only, never named patients, at the same fees.
Why Clinical Speed
Growth your own patients already justify, sized before you spend a dollar on a device, training or space.
Built on the payer coverage rules, your provider types and your own diagnoses. A planning report, never a patient list.
Estimates are labelled as upper bounds, and after a launch the line is measured only on what it collects in your 835s.
Data and guardrails
One suite installation, then a share of what a new line collects in its first year, set in the proposal.
Request a proposalClinical Speed Forward · one connected engine
Request a demo
The demo runs on the de-identified Demo Hospital account. Courtney Garner, our Chief Operating Officer, schedules every demo and leads the discovery conversation.